Health Care & Life Sciences » Pharmaceuticals | Jaguar Animal Health Inc.

Jaguar Animal Health Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
258.40
141.50
4,361.20
4,416.10
Cost of Goods Sold (COGS) incl. D&A
-
-
128.60
99.50
1,202.60
2,765.70
Gross Income
-
-
129.80
42.10
3,158.60
1,650.40
SG&A Expense
783.00
8,315.70
12,575.10
13,628.00
14,701.40
27,263.50
EBIT
783.00
8,315.70
12,445.40
13,586.00
11,542.80
25,613.20
Unusual Expense
-
51.40
501.60
151.20
22,477.00
4,219.90
Non Operating Income/Expense
-
-
27.30
11.10
79.60
315.70
Interest Expense
18.30
345.30
3,317.30
985.50
1,209.60
2,628.70
Pretax Income
801.20
8,609.60
16,291.60
14,733.80
35,149.90
32,146.10
Income Tax
-
-
-
-
13,181.20
-
Consolidated Net Income
801.20
9,256.20
16,291.60
14,733.80
21,968.60
32,146.10
Net Income
801.20
9,256.20
16,291.60
14,733.80
21,968.60
32,146.10
Net Income After Extraordinaries
801.20
9,256.20
16,291.60
14,733.80
21,968.60
32,146.10
Net Income Available to Common
801.20
9,256.20
16,637.90
14,733.80
21,968.60
32,146.10
EPS (Basic)
1.41
48.60
40.50
20.25
7.65
153.27
Basic Shares Outstanding
569.90
-
-
-
2,895.70
209.70
EPS (Diluted)
1.41
-
-
-
7.59
153.27
Diluted Shares Outstanding
569.90
-
-
-
2,895.70
209.70
EBITDA
-
8,315.70
12,440.20
13,538.50
10,958.50
23,865.60
Other After Tax Income (Expense)
-
646.70
-
-
-
-
Preferred Dividends
-
-
346.40
-
-
-

About Jaguar Animal Health

View Profile
Address
201 Mission Street
San Francisco California 94105
United States
Employees -
Website http://www.jaguar.health
Updated 07/08/2019
Jaguar Health, Inc. engages in the dvelopment of gastrointestinal products for both human prescription use and animals. Its products include Mytesi, Canalevia, Equilevia, and Neonorm. The Mytesi product IS use for relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.